近六成主动权益基金年内收益转正，医药主题强势领跑半程业绩榜

Group 1 - The A-share market has shown a rebound since April 7, with the Wind偏股混合型基金指数 rising over 11% as of June 17, indicating a recovery in active equity products [1][2] - Nearly 70% of active equity funds have turned positive in returns, with 3,079 out of 4,462 funds reporting gains, a significant increase from 10.8% on April 7 [2][3] - The top-performing funds are heavily invested in the pharmaceutical sector, with six out of the top ten funds focusing on this area, driven by Hong Kong innovative drug stocks [3][5] Group 2 - The top fund, 长城医药产业精选A, has achieved a 75.69% return year-to-date, followed closely by 中信建投北交所精选两年定开A and 永赢医药创新智选A with returns of 74% and 70.8% respectively [3] - The performance of the pharmaceutical sector is attributed to the strong showing of Hong Kong innovative drug stocks, which constitute a significant portion of the holdings in these funds [3][6] - Despite recent market corrections in popular sectors like innovative drugs and new consumption, industry experts believe that the long-term value remains intact, with ongoing support from national policies and market demand [5][6] Group 3 - The innovative drug sector has seen a year-to-date increase of 59.18%, while other sectors like humanoid robots and new consumption have also performed well, with gains exceeding 20% [5] - Recent corrections in these sectors are viewed as technical adjustments rather than a sign of a downturn, with analysts suggesting continued investment interest in innovative drugs due to their long-term growth potential [6][7] - The new consumption sector is experiencing a temporary pullback, but the underlying market conditions remain strong, as evidenced by positive consumption data during the recent 618 shopping festival [6][7]